Transplant immunology最新文献_第3页

Novel, short-course, low-dose total lymphoid irradiation (TLI) post heart transplant for recalcitrant rejection – A single centre experience 新型、短疗程、低剂量全淋巴细胞照射（TLI）治疗心脏移植后顽固性排斥反应-单中心经验。

IF 1.4 4区医学 Q4 IMMUNOLOGY

Transplant immunology

Pub Date : 2025-11-29 DOI: 10.1016/j.trim.2025.102333

Felicity Lee , B.N. Clare Fazackerley , Tee S. Lim , Lloyd D'Orsogna , Jon Downing , Linh Truong , Amit Shah , Jay Baumwol , Kaitlyn Lam , James Lambert , Peter Dias , Faith Njue , Lawrence Dembo

Background

A previous small study (2007) of patients who received short-course, low-dose total lymphoid irradiation (sTLI) as treatment for recalcitrant cardiac rejection post-heart transplantation (HTx) reported good treatment compliance without significant toxicities and improvement in rejection frequency. We conducted a retrospective analysis, evaluating longer-term outcomes in this patient cohort.

Methods and results

We reviewed the medical records of 21 HTx recipients (mean age ± std. 43.7 ± 12.8 years; 47.6 % female) who received sTLI between 2001 and 2023. Five patients were highly sensitized pre-HTx (calculated panel-reactive antibody >80 %) and 8 patients received induction immunosuppression at time of HTx. Patients received 4.5Gy in four fractions over 4 consecutive days administered (n = 13 as an outpatient), at a median of 442 (IQR 47–966) days post-HTx. STLI was well-tolerated symptomatically with no persistent lymphopenias. Eleven patients had no further rejection. Ten patients had immediate rejection resolution with later rejection detected (median 401 [IQR 301–1569] days post-sTLI). Thirteen patients, mostly transplanted pre-2010, have deceased (median graft survival 7.6 years, mean follow-up 9.4 years). One patient died of metastatic colon cancer. There were no haematological malignancies. Two patients received a second sTLI course and subsequent re-HTx.

Conclusions

We report the largest case series of patients who received sTLI post-HTx. STLI is well-tolerated, with resolution of immediate recalcitrant rejection in all patients and resolution of rejection in the longer term in 52 %. STLI is a possible alternative option for patients with cardiac rejection refractory to routine, augmented immunotherapy. Further larger studies are required to assess the longer-term efficacy and safety of this treatment.

背景：之前的一项小型研究（2007年）对接受短疗程、低剂量全淋巴细胞照射（sTLI）治疗心脏移植后顽固性心脏排斥反应（HTx）的患者进行了研究，报告了良好的治疗依从性，没有明显的毒性和排斥反应频率的改善。我们进行了回顾性分析，评估该患者队列的长期结果。方法与结果：我们回顾了21例HTx受者（平均年龄 ± ）的病历。 43.7±12.8  年;47.6 %女性)，在2001年至2023年间接受sTLI治疗。5例患者在HTx前高度致敏（计算出面板反应抗体>80 %），8例患者在HTx时接受诱导免疫抑制。患者在连续4天内分四部分接受4.5Gy （n = 13，作为门诊患者），htx后中位数为442 （IQR 47-966）天。STLI在症状上耐受良好，无持续性淋巴细胞减少。11名患者没有出现进一步的排斥反应。10例患者即刻排异反应消退，随后发现排异反应（stli后中位401 [IQR 301-1569]天）。13例患者，大多数在2010年前移植，已经死亡（中位移植生存7.6 年，平均随访9.4 年）。一名患者死于转移性结肠癌。无血液学恶性肿瘤。两名患者接受了第二次sTLI治疗，随后再次接受htx治疗。结论：我们报道了htx术后接受sTLI的最大病例系列。STLI耐受性良好，所有患者立即出现顽固性排斥反应，52% %的患者长期出现排斥反应。STLI是对常规增强免疫治疗难治性心脏排斥患者的一种可能的替代选择。需要更大规模的研究来评估这种治疗的长期疗效和安全性。

{"title":"Novel, short-course, low-dose total lymphoid irradiation (TLI) post heart transplant for recalcitrant rejection – A single centre experience","authors":"Felicity Lee , B.N. Clare Fazackerley , Tee S. Lim , Lloyd D'Orsogna , Jon Downing , Linh Truong , Amit Shah , Jay Baumwol , Kaitlyn Lam , James Lambert , Peter Dias , Faith Njue , Lawrence Dembo","doi":"10.1016/j.trim.2025.102333","DOIUrl":"10.1016/j.trim.2025.102333","url":null,"abstract":"<div><h3>Background</h3><div>A previous small study (2007) of patients who received short-course, low-dose total lymphoid irradiation (sTLI) as treatment for recalcitrant cardiac rejection post-heart transplantation (HTx) reported good treatment compliance without significant toxicities and improvement in rejection frequency. We conducted a retrospective analysis, evaluating longer-term outcomes in this patient cohort.</div></div><div><h3>Methods and results</h3><div>We reviewed the medical records of 21 HTx recipients (mean age ± std. 43.7 ± 12.8 years; 47.6 % female) who received sTLI between 2001 and 2023. Five patients were highly sensitized pre-HTx (calculated panel-reactive antibody >80 %) and 8 patients received induction immunosuppression at time of HTx. Patients received 4.5Gy in four fractions over 4 consecutive days administered (<em>n</em> = 13 as an outpatient), at a median of 442 (IQR 47–966) days post-HTx. STLI was well-tolerated symptomatically with no persistent lymphopenias. Eleven patients had no further rejection. Ten patients had immediate rejection resolution with later rejection detected (median 401 [IQR 301–1569] days post-sTLI). Thirteen patients, mostly transplanted pre-2010, have deceased (median graft survival 7.6 years, mean follow-up 9.4 years). One patient died of metastatic colon cancer. There were no haematological malignancies. Two patients received a second sTLI course and subsequent re-HTx.</div></div><div><h3>Conclusions</h3><div>We report the largest case series of patients who received sTLI post-HTx. STLI is well-tolerated, with resolution of immediate recalcitrant rejection in all patients and resolution of rejection in the longer term in 52 %. STLI is a possible alternative option for patients with cardiac rejection refractory to routine, augmented immunotherapy. Further larger studies are required to assess the longer-term efficacy and safety of this treatment.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"94 ","pages":"Article 102333"},"PeriodicalIF":1.4,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145655374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Conversion to belatacept-based immunosuppression as a calcineurin sparing regimen in lung transplant: A multi-institutional retrospective study 在肺移植中转换为基于belataccept的免疫抑制作为钙调磷酸酶保留方案：一项多机构回顾性研究。

IF 1.4 4区医学 Q4 IMMUNOLOGY

Transplant immunology

Pub Date : 2025-11-29 DOI: 10.1016/j.trim.2025.102330

Moustafa Younis , Cecelia M. Miller , Christopher I. Mederos , Ariana Ishaq , Pooja Kumar , Biplab Saha , Cynthia Gries , Victoria Reams , Vaidehi Kaza , Srinivas Bollineni , Fernando Torres , Mohammad A. Aladaileh , Mindaugas Rackauskas , Irina Timofte , Amir Emtiazjoo

Background

Calcineurin inhibitor (CNI) related kidney dysfunction is common and associated with worse outcomes after lung transplantation (LTx). To mitigate that risk, belatacept use in a CNI-sparing regimen is an alternative in LTx. We aim to describe our experience using belatacept as a CNI-sparing regimen in LTx.

Methods

A multi-institutional retrospective review of LTx patients who received belatacept (1/2018–8/2023) was performed. The primary outcome is the change in estimated glomerular filtration rate (eGFR) after initiation of belatacept. Secondary outcomes were compared with a control group of patients transplanted during 1/2018–8/2023 that did not receive belatacept. Secondary outcomes include acute cellular rejection (ACR), denovo donor specific antibodies (DSA), antibody mediated rejection (AMR), infections, malignancy, chronic lung allograft dysfunction (CLAD) and mortality.

Results

A total of 170 LTx patients who received belatacept were included for the primary outcome. To investigate the secondary outcomes an additional 288 LTx controls were used. The median (IQR) eGFR at the time of belatacept initiation, six months, and one year post belatacept initiation was 43 (34–52), 46 (37–53) and 43 (36–53) mL/min/1.73 m2, respectively (p = 0.21). There was no significant difference in ACR, DSA, AMR, infections, malignancy, CLAD or mortality between both groups.

Conclusions

Belatacept CNI-sparing therapy was well tolerated and feasible in LTx recipients, with renal function appearing to stabilize over time and no apparent safety signal for acute rejection, infection, malignancy, CLAD, or mortality.

背景：钙调磷酸酶抑制剂（CNI）相关的肾功能障碍是常见的，并且与肺移植（LTx）后较差的预后相关。为了减轻这种风险，在LTx中，在cni保留方案中使用belataccept是一种替代方案。我们的目的是描述我们在LTx中使用belataccept作为cni保护方案的经验。方法：对接受belataccept治疗的LTx患者（2018年1月- 2023年8月）进行多机构回顾性分析。主要结局是开始服用后估计肾小球滤过率（eGFR）的变化。次要结果与2018年1月至2023年8月期间未接受belataccept的移植患者的对照组进行比较。次要结局包括急性细胞排斥反应（ACR）、首发供体特异性抗体（DSA）、抗体介导的排斥反应（AMR）、感染、恶性肿瘤、慢性同种异体肺功能障碍（CLAD）和死亡率。结果：共有170例LTx患者接受了belataccept纳入主要结局。为了调查次要结果，另外使用了288例LTx对照。belatacept起始时、起始后6个月和1年的中位（IQR） eGFR分别为43（34-52）、46（37-53）和43 (36-53)mL/min/1.73 m2 （p = 0.21）。两组间ACR、DSA、AMR、感染、恶性、覆层及死亡率无显著差异。结论：在LTx受者中，Belatacept保留cni治疗耐受性良好且可行，肾功能随着时间的推移趋于稳定，并且没有明显的排斥反应、感染、恶性肿瘤、CLAD或死亡率的安全信号。

{"title":"Conversion to belatacept-based immunosuppression as a calcineurin sparing regimen in lung transplant: A multi-institutional retrospective study","authors":"Moustafa Younis , Cecelia M. Miller , Christopher I. Mederos , Ariana Ishaq , Pooja Kumar , Biplab Saha , Cynthia Gries , Victoria Reams , Vaidehi Kaza , Srinivas Bollineni , Fernando Torres , Mohammad A. Aladaileh , Mindaugas Rackauskas , Irina Timofte , Amir Emtiazjoo","doi":"10.1016/j.trim.2025.102330","DOIUrl":"10.1016/j.trim.2025.102330","url":null,"abstract":"<div><h3>Background</h3><div>Calcineurin inhibitor (CNI) related kidney dysfunction is common and associated with worse outcomes after lung transplantation (LTx). To mitigate that risk, belatacept use in a CNI-sparing regimen is an alternative in LTx. We aim to describe our experience using belatacept as a CNI-sparing regimen in LTx.</div></div><div><h3>Methods</h3><div>A multi-institutional retrospective review of LTx patients who received belatacept (1/2018–8/2023) was performed. The primary outcome is the change in estimated glomerular filtration rate (eGFR) after initiation of belatacept. Secondary outcomes were compared with a control group of patients transplanted during 1/2018–8/2023 that did not receive belatacept. Secondary outcomes include acute cellular rejection (ACR), denovo donor specific antibodies (DSA), antibody mediated rejection (AMR), infections, malignancy, chronic lung allograft dysfunction (CLAD) and mortality.</div></div><div><h3>Results</h3><div>A total of 170 LTx patients who received belatacept were included for the primary outcome. To investigate the secondary outcomes an additional 288 LTx controls were used. The median (IQR) eGFR at the time of belatacept initiation, six months, and one year post belatacept initiation was 43 (34–52), 46 (37–53) and 43 (36–53) mL/min/1.73 m2, respectively (<em>p</em> = 0.21). There was no significant difference in ACR, DSA, AMR, infections, malignancy, CLAD or mortality between both groups.</div></div><div><h3>Conclusions</h3><div>Belatacept CNI-sparing therapy was well tolerated and feasible in LTx recipients, with renal function appearing to stabilize over time and no apparent safety signal for acute rejection, infection, malignancy, CLAD, or mortality.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"94 ","pages":"Article 102330"},"PeriodicalIF":1.4,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145655446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Smart transplant+: A HyCARE hybrid AI–cloud framework for intelligent donor–recipient matching, workflow automation, and post-transplant optimization 智能移植+:HyCARE混合人工智能云框架，用于智能供体-受体匹配、工作流程自动化和移植后优化。

IF 1.4 4区医学 Q4 IMMUNOLOGY

Transplant immunology

Pub Date : 2025-11-27 DOI: 10.1016/j.trim.2025.102332

Winner Pulakhandam , Archana Chaluvadi , Visrutatma Rao Vallu , R. Padmavathy

Organ transplantation is a life-saving medical intervention to reverse end-stage organ failure. Despite its life-saving potential, organ transplantation faces inefficiencies like organ shortages, long wait times, and rejection risks due to manual, clinically limited donor-recipient matching. The rapid growth of AI and cloud computing offers new opportunities to enhance organ transplantation. This study proposes Smart Transplant+, a HyCARE system enabling intelligent matching, decision-making, and process automation. The architecture leverages a huge Organ Transplant Dataset and the most advanced methods such as Feedforward Neural Networks and Genetic Algorithms to maximize donor-recipient matching. Gated Recurrent Units are utilized in pre-transplant risk prediction, and post-transplant care is augmented with real-time tracking by IoT-based wearable sensors. The system has been programmed using Python, along with software tools like TensorFlow for machine learning and AES encryption for secure data storage and transmission. The Smart Transplant+ system provides 95–98 % accuracy which is higher than existing methods in identifying suitable donors and recipients and the potential for successful transplantation, and greatly enhances organ transplant efficiency and success rate. This book illustrates the revolutionary potential of synergizing IoT, cloud technology, and AI to optimize transplant care and improve outcomes.

器官移植是一种挽救生命的医疗干预措施，以逆转终末期器官衰竭。尽管器官移植具有挽救生命的潜力，但由于人工、临床有限的供体-受体匹配，器官移植面临着器官短缺、等待时间长和排斥风险等低效率问题。人工智能和云计算的快速发展为加强器官移植提供了新的机遇。本研究提出了智能移植+，一个HyCARE系统，实现智能匹配，决策和过程自动化。该架构利用巨大的器官移植数据集和最先进的方法，如前馈神经网络和遗传算法，以最大限度地实现供体-受体匹配。门控复发单元用于移植前风险预测，移植后护理通过基于物联网的可穿戴传感器进行实时跟踪。该系统使用Python编程，以及用于机器学习的TensorFlow和用于安全数据存储和传输的AES加密等软件工具。智能移植+系统在识别合适的供体和受体以及移植成功的可能性方面提供95-98 %的准确率，大大提高了器官移植的效率和成功率。这本书说明了协同物联网、云技术和人工智能优化移植护理和改善结果的革命性潜力。

{"title":"Smart transplant+: A HyCARE hybrid AI–cloud framework for intelligent donor–recipient matching, workflow automation, and post-transplant optimization","authors":"Winner Pulakhandam , Archana Chaluvadi , Visrutatma Rao Vallu , R. Padmavathy","doi":"10.1016/j.trim.2025.102332","DOIUrl":"10.1016/j.trim.2025.102332","url":null,"abstract":"<div><div>Organ transplantation is a life-saving medical intervention to reverse end-stage organ failure. Despite its life-saving potential, organ transplantation faces inefficiencies like organ shortages, long wait times, and rejection risks due to manual, clinically limited donor-recipient matching. The rapid growth of AI and cloud computing offers new opportunities to enhance organ transplantation. This study proposes Smart Transplant+, a HyCARE system enabling intelligent matching, decision-making, and process automation. The architecture leverages a huge Organ Transplant Dataset and the most advanced methods such as Feedforward Neural Networks and Genetic Algorithms to maximize donor-recipient matching. Gated Recurrent Units are utilized in pre-transplant risk prediction, and post-transplant care is augmented with real-time tracking by IoT-based wearable sensors. The system has been programmed using Python, along with software tools like TensorFlow for machine learning and AES encryption for secure data storage and transmission. The Smart Transplant+ system provides 95–98 % accuracy which is higher than existing methods in identifying suitable donors and recipients and the potential for successful transplantation, and greatly enhances organ transplant efficiency and success rate. This book illustrates the revolutionary potential of synergizing IoT, cloud technology, and AI to optimize transplant care and improve outcomes.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"94 ","pages":"Article 102332"},"PeriodicalIF":1.4,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145640344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics linking ischemia-reperfusion to chronic lung allograft dysfunction in lung transplantation: A single-cell bioinformatics analysis 肺移植中缺血-再灌注与慢性同种异体肺移植物功能障碍相关的特征：单细胞生物信息学分析。

IF 1.4 4区医学 Q4 IMMUNOLOGY

Transplant immunology

Pub Date : 2025-11-12 DOI: 10.1016/j.trim.2025.102326

Peng Zhang , Zhendong Qiao , Song Zhao , Kai Wu

Background

Lung transplantation offers a life-saving procedure to patients with end-stage lung diseases with 85–89 % one year and 60 % five-year survival rates. Lung transplants are complicated by early ischemia/reperfusion injury (IRI) and late chronic lung allograft dysfunction (CLAD). However, the cellular and molecular links between IRI and CLAD remain unclear.

Materials and methods

We integrated single-cell RNA-seq results from GSE220797 and GSE224210 data sets. After quality filtering, we performed Louvain clustering and UMAP visualization. We applied Augur method to prioritize cell populations by transcriptional responsiveness to IRI and CLAD. We also performed dynamic trajectory analyses to map pseudotemporal transitions. Pathway activity was characterized by differential expression analysis and module scoring. Intercellular communication was assessed using CellChat and MEBOCOST analyses. Regulon inference was performed with pySCENIC analysis.

Results

Overall, epithelial cells showed progressive metabolic suppression and activation of cuproptosis, a programmed cell death (PCD) triggered by excessive copper accumulation within cells. Club cells, found in the small airways of the lungs, exhibited developmental plasticity and predictive potential across IRI and CLAD conditions. Among myeloid populations, M1 proinflammatory (AM_M1TM) macrophages underwent macrophage-to-myofibroblast transition (MMT) and produced excessive extracellular matrix (ECM) supporting a network of proteins surrounding cells. Metabolite and cell–cell communication analyses revealed declining macrophage/epithelial metabolic crosstalk and differential signaling flux from normal through IRI to CLAD transition.

Conclusions

The integrated single-cell atlas delineates interaction of multiple cells and their signaling pathways linking IRI to CLAD processes. These findings require further verification through studies in animal models and clinical samples.

背景：肺移植为终末期肺病患者提供了一种挽救生命的手术，其一年生存率为85-89 %，五年生存率为60 %。肺移植并发早期缺血/再灌注损伤（IRI）和晚期慢性同种异体肺功能障碍（CLAD）。然而，IRI和CLAD之间的细胞和分子联系尚不清楚。材料和方法：我们整合了来自GSE220797和GSE224210数据集的单细胞RNA-seq结果。经过质量过滤后，我们进行了Louvain聚类和UMAP可视化。我们应用Augur方法通过对IRI和CLAD的转录反应来确定细胞群的优先级。我们还进行了动态轨迹分析来映射伪时间转换。通过差异表达分析和模块评分来表征通路活性。使用CellChat和MEBOCOST分析评估细胞间通信。用pySCENIC分析进行规律推理。结果：总体而言，上皮细胞表现出进行性代谢抑制和铜增生的激活，这是一种由细胞内过量铜积累引发的程序性细胞死亡（PCD）。在肺小气道中发现的俱乐部细胞在IRI和CLAD条件下表现出发育可塑性和预测潜力。在髓系人群中，M1促炎（AM_M1TM）巨噬细胞经历巨噬细胞到肌成纤维细胞的转化（MMT），并产生过多的细胞外基质（ECM），支持细胞周围的蛋白质网络。代谢物和细胞间通讯分析显示，巨噬细胞/上皮代谢串音下降，从正常到IRI到CLAD转变的差异信号通量下降。结论：整合的单细胞图谱描述了多个细胞的相互作用及其连接IRI和CLAD过程的信号通路。这些发现需要通过动物模型和临床样本的研究进一步验证。

{"title":"Characteristics linking ischemia-reperfusion to chronic lung allograft dysfunction in lung transplantation: A single-cell bioinformatics analysis","authors":"Peng Zhang , Zhendong Qiao , Song Zhao , Kai Wu","doi":"10.1016/j.trim.2025.102326","DOIUrl":"10.1016/j.trim.2025.102326","url":null,"abstract":"<div><h3>Background</h3><div>Lung transplantation offers a life-saving procedure to patients with end-stage lung diseases with 85–89 % one year and 60 % five-year survival rates. Lung transplants are complicated by early ischemia/reperfusion injury (IRI) and late chronic lung allograft dysfunction (CLAD). However, the cellular and molecular links between IRI and CLAD remain unclear.</div></div><div><h3>Materials and methods</h3><div>We integrated single-cell RNA-seq results from <span><span>GSE220797</span><svg><path></path></svg></span> and <span><span>GSE224210</span><svg><path></path></svg></span> data sets. After quality filtering, we performed Louvain clustering and UMAP visualization. We applied Augur method to prioritize cell populations by transcriptional responsiveness to IRI and CLAD. We also performed dynamic trajectory analyses to map pseudotemporal transitions. Pathway activity was characterized by differential expression analysis and module scoring. Intercellular communication was assessed using CellChat and MEBOCOST analyses. Regulon inference was performed with pySCENIC analysis.</div></div><div><h3>Results</h3><div>Overall, epithelial cells showed progressive metabolic suppression and activation of cuproptosis, a programmed cell death (PCD) triggered by excessive copper accumulation within cells. Club cells, found in the small airways of the lungs, exhibited developmental plasticity and predictive potential across IRI and CLAD conditions. Among myeloid populations, M1 proinflammatory (AM_M1TM) macrophages underwent macrophage-to-myofibroblast transition (MMT) and produced excessive extracellular matrix (ECM) supporting a network of proteins surrounding cells. Metabolite and cell–cell communication analyses revealed declining macrophage/epithelial metabolic crosstalk and differential signaling flux from normal through IRI to CLAD transition.</div></div><div><h3>Conclusions</h3><div>The integrated single-cell atlas delineates interaction of multiple cells and their signaling pathways linking IRI to CLAD processes. These findings require further verification through studies in animal models and clinical samples.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"93 ","pages":"Article 102326"},"PeriodicalIF":1.4,"publicationDate":"2025-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune mediators as therapeutic targets in GvHD; cytokines, growth factors, chemokines, and co-stimulation /co-inhibition 免疫介质作为GvHD的治疗靶点细胞因子、生长因子、趋化因子和共刺激/共抑制

IF 1.4 4区医学 Q4 IMMUNOLOGY

Transplant immunology

Pub Date : 2025-11-12 DOI: 10.1016/j.trim.2025.102328

Amir Rastegari , Fatemeh Mohebbi

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) and emerging allogeneic T cell–based immunotherapies offer curative potential for hematologic malignancies, solid tumors, and selected non-malignant disorders through graft-versus-tumor (GvT) and immune reconstitution effects mediated by donor immune cells. However, their clinical success is constrained by graft-versus-host disease (GvHD) and other immune-mediated toxicities resulting from donor–host alloreactivity. Therefore, a central challenge is to develop personalized, safer allogeneic cellular therapies that preserve potent anti-tumor and immune-restorative functions while minimizing tissue injury. This review integrates the current understanding of acute and chronic GvHD immunopathogenesis, covering cytokine and chemokine networks, growth-factor signaling, and co-stimulatory/co-inhibitory pathways, and links these mechanisms to therapeutic strategies for selective immune modulation. Drawing on translational insights, we propose a framework for next-generation allogeneic cell-based therapies that are precision-tuned to donor/recipient biology, advancing individualized anticancer and immune-reconstitution outcomes with improved safety.

同种异体造血干细胞移植（allog - hsct）和新兴的基于同种异体T细胞的免疫疗法通过移植物抗肿瘤（GvT）和供体免疫细胞介导的免疫重建效应，为血液系统恶性肿瘤、实体瘤和某些非恶性疾病提供了治疗潜力。然而，它们的临床成功受到移植物抗宿主病（GvHD）和其他由供体-宿主异体反应性引起的免疫介导毒性的限制。因此，一个核心挑战是开发个性化的、更安全的同种异体细胞疗法，在最大限度地减少组织损伤的同时，保持有效的抗肿瘤和免疫恢复功能。本文综述了目前对急性和慢性GvHD免疫发病机制的理解，包括细胞因子和趋化因子网络、生长因子信号传导和共刺激/共抑制途径，并将这些机制与选择性免疫调节的治疗策略联系起来。利用翻译的见解，我们提出了下一代基于同种异体细胞的治疗框架，该框架精确调整为供体/受体生物学，在提高安全性的同时推进个体化抗癌和免疫重建结果。

{"title":"Immune mediators as therapeutic targets in GvHD; cytokines, growth factors, chemokines, and co-stimulation /co-inhibition","authors":"Amir Rastegari , Fatemeh Mohebbi","doi":"10.1016/j.trim.2025.102328","DOIUrl":"10.1016/j.trim.2025.102328","url":null,"abstract":"<div><div>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) and emerging allogeneic T cell–based immunotherapies offer curative potential for hematologic malignancies, solid tumors, and selected non-malignant disorders through graft-versus-tumor (GvT) and immune reconstitution effects mediated by donor immune cells. However, their clinical success is constrained by graft-versus-host disease (GvHD) and other immune-mediated toxicities resulting from donor–host alloreactivity. Therefore, a central challenge is to develop personalized, safer allogeneic cellular therapies that preserve potent anti-tumor and immune-restorative functions while minimizing tissue injury. This review integrates the current understanding of acute and chronic GvHD immunopathogenesis, covering cytokine and chemokine networks, growth-factor signaling, and co-stimulatory/co-inhibitory pathways, and links these mechanisms to therapeutic strategies for selective immune modulation. Drawing on translational insights, we propose a framework for next-generation allogeneic cell-based therapies that are precision-tuned to donor/recipient biology, advancing individualized anticancer and immune-reconstitution outcomes with improved safety.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"93 ","pages":"Article 102328"},"PeriodicalIF":1.4,"publicationDate":"2025-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145516906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence and determinants of frailty–sarcopenia comorbidity in hospitalized patients undergoing liver transplantation for hepatic echinococcosis 因肝包虫病接受肝移植的住院患者虚弱-肌肉减少合并症的患病率和决定因素。

IF 1.4 4区医学 Q4 IMMUNOLOGY

Transplant immunology

Pub Date : 2025-11-11 DOI: 10.1016/j.trim.2025.102327

Sujun Wang , Huanhuan Wei , Yiliyaer Aihemaiti , Lijun Ma , Ying Tong , Fang Li

Objective

The aim of this study was to examine the prevalence and influencing factors of comorbid frailty and sarcopenia in hospitalized patients with hepatic echinococcosis undergoing liver transplantation, thereby providing evidence for targeted clinical interventions.

Methods

A convenience sampling method was used to recruit 118 patients who underwent liver transplantation and were hospitalized in the hepatobiliary echinococcosis departments of two tertiary grade A hospitals in Urumqi from March 2023 to July 2025. Data were collected using a general information questionnaire, the Liver Frailty Index (LFI), a sarcopenia screening questionnaire, the Social Support Rating Scale (SSRS), and a general health status scale. Univariate analyses were performed using analysis of variance (ANOVA), χ² tests, or non-parametric tests, as appropriate. Logistic regression analysis was conducted to identify factors associated with preoperative comorbidity of frailty and sarcopenia in liver transplant recipients.

Results

Valid data were obtained from 114 patients. The prevalence of comorbid frailty and sarcopenia in this patient population was 25.44 %. Logistic regression analysis indicated that older age, a higher number of comorbid chronic diseases, lower hemoglobin levels, and reduced social support were independent determinants (p < 0.05).

Conclusions

Comorbid frailty and sarcopenia were relatively prevalent among hospitalized patients with hepatic echinococcosis undergoing liver transplantation. Comprehensive preoperative evaluations should be conducted to identify these comorbidities, and targeted intervention strategies should be implemented promptly based on the identified determinants to mitigate disease progression.

目的：探讨肝包虫病住院肝移植患者伴发虚弱和肌肉减少症的患病率及影响因素，为有针对性的临床干预提供依据。方法：采用方便抽样的方法，选取乌鲁木齐市两家三级甲等医院肝胆包虫病科于2023年3月至2025年7月住院的肝移植患者118例。数据收集采用一般信息问卷、肝衰竭指数（LFI）、肌肉减少症筛查问卷、社会支持评定量表（SSRS）和一般健康状况量表。采用方差分析（ANOVA）、χ2检验或适当的非参数检验进行单因素分析。进行Logistic回归分析，以确定肝移植受者术前虚弱和肌肉减少的合并症相关因素。结果：114例患者获得有效资料。该患者群体中合并虚弱和肌肉减少症的患病率为25.44% %。Logistic回归分析显示，年龄较大、慢性病合并症较多、血红蛋白水平较低、社会支持减少是独立决定因素（p ）。结论：肝包虫病住院肝移植患者合并症虚弱和肌肉减少相对普遍。应进行全面的术前评估，以确定这些合并症，并应根据确定的决定因素迅速实施有针对性的干预策略，以减轻疾病进展。

{"title":"Prevalence and determinants of frailty–sarcopenia comorbidity in hospitalized patients undergoing liver transplantation for hepatic echinococcosis","authors":"Sujun Wang , Huanhuan Wei , Yiliyaer Aihemaiti , Lijun Ma , Ying Tong , Fang Li","doi":"10.1016/j.trim.2025.102327","DOIUrl":"10.1016/j.trim.2025.102327","url":null,"abstract":"<div><h3>Objective</h3><div>The aim of this study was to examine the prevalence and influencing factors of comorbid frailty and sarcopenia in hospitalized patients with hepatic echinococcosis undergoing liver transplantation, thereby providing evidence for targeted clinical interventions.</div></div><div><h3>Methods</h3><div>A convenience sampling method was used to recruit 118 patients who underwent liver transplantation and were hospitalized in the hepatobiliary echinococcosis departments of two tertiary grade A hospitals in Urumqi from March 2023 to July 2025. Data were collected using a general information questionnaire, the Liver Frailty Index (LFI), a sarcopenia screening questionnaire, the Social Support Rating Scale (SSRS), and a general health status scale. Univariate analyses were performed using analysis of variance (ANOVA), χ<sup>2</sup> tests, or non-parametric tests, as appropriate. Logistic regression analysis was conducted to identify factors associated with preoperative comorbidity of frailty and sarcopenia in liver transplant recipients.</div></div><div><h3>Results</h3><div>Valid data were obtained from 114 patients. The prevalence of comorbid frailty and sarcopenia in this patient population was 25.44 %. Logistic regression analysis indicated that older age, a higher number of comorbid chronic diseases, lower hemoglobin levels, and reduced social support were independent determinants (<em>p</em> < 0.05).</div></div><div><h3>Conclusions</h3><div>Comorbid frailty and sarcopenia were relatively prevalent among hospitalized patients with hepatic echinococcosis undergoing liver transplantation. Comprehensive preoperative evaluations should be conducted to identify these comorbidities, and targeted intervention strategies should be implemented promptly based on the identified determinants to mitigate disease progression.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"93 ","pages":"Article 102327"},"PeriodicalIF":1.4,"publicationDate":"2025-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Women recipients are at high risk for biopsy-proven acute rejection in spouse kidney transplantation 女性受者在配偶肾移植中发生活检证实的急性排斥反应的风险很高。

IF 1.4 4区医学 Q4 IMMUNOLOGY

Transplant immunology

Pub Date : 2025-11-01 DOI: 10.1016/j.trim.2025.102324

Sulin Luo , Meifang Wang , Xingxia Wang , Tianlu Zhang , Luying Guo , Pengpeng Yan , Junhao Lv , Hongfeng Huang , Wenhan Peng , Jianyong Wu , Jingyi Zhou , Jianghua Chen , Rending Wang

Background

Spouse kidney transplantation represents a significant source of kidney donations. However, gender dynamics often result in husbands being recipients and wives being donors. Research on the immunological rejection and prognosis in wife recipients—who may develop immune memory due to pregnancy or sexual contact but lack preformed antibodies before transplantation—remains limited.

Methods

This retrospective study analyzed 164 patients who underwent living spousal kidney transplantation at the First Affiliated Hospital of Zhejiang University between July 2007 and December 2021, with follow-up until December 2023.

Results

The study included 33 husband-to-wife transplant cases (Group W) and 131 wife-to-husband cases (Group H). Donors in Group W were older, had higher serum creatinine (SCr) levels, and donated heavier kidneys compared with donors in Group H (p < 0.05). Group W recipients had a significantly higher incidence of biopsy-proven acute rejection within two years post-transplant than Group H. The rejection reversal rate in Group W (5/6, 83.3 %) was also higher than in Group H (2/7, 28.6%) during the same period. Postoperative follow-up revealed that Group H had significantly higher SCr levels and relatively lower estimated glomerular filtration rate (eGFR) than Group W. Additionally, Group H exhibited a slightly higher mortality rate.

Conclusions

Wife recipients experienced a higher incidence of biopsy-proven acute rejection but demonstrated lower SCr levels and higher eGFR within two years post-transplant. This outcome may be largely explained by the greater kidney weight of male donors.

背景：配偶肾移植是肾脏捐献的重要来源。然而，性别动态往往导致丈夫是接受者，妻子是捐赠者。由于怀孕或性接触可能产生免疫记忆，但在移植前缺乏预先形成的抗体，对妻子受体的免疫排斥和预后的研究仍然有限。方法：回顾性分析2007年7月至2021年12月在浙江大学第一附属医院行配偶活体肾移植的164例患者，随访至2023年12月。结果：本研究包括33例夫妻间移植（W组）和131例夫妻间移植（H组）。与H组相比，W组的供者年龄较大，血清肌酐（SCr）水平较高，捐献的肾脏较重（p ）。结论：妻子受体在移植后两年内经历了较高的活检证实的急性排斥反应发生率，但SCr水平较低，eGFR较高。这一结果在很大程度上可以解释为男性捐赠者的肾脏重量更大。

{"title":"Women recipients are at high risk for biopsy-proven acute rejection in spouse kidney transplantation","authors":"Sulin Luo , Meifang Wang , Xingxia Wang , Tianlu Zhang , Luying Guo , Pengpeng Yan , Junhao Lv , Hongfeng Huang , Wenhan Peng , Jianyong Wu , Jingyi Zhou , Jianghua Chen , Rending Wang","doi":"10.1016/j.trim.2025.102324","DOIUrl":"10.1016/j.trim.2025.102324","url":null,"abstract":"<div><h3>Background</h3><div>Spouse kidney transplantation represents a significant source of kidney donations. However, gender dynamics often result in husbands being recipients and wives being donors. Research on the immunological rejection and prognosis in wife recipients—who may develop immune memory due to pregnancy or sexual contact but lack preformed antibodies before transplantation—remains limited.</div></div><div><h3>Methods</h3><div>This retrospective study analyzed 164 patients who underwent living spousal kidney transplantation at the First Affiliated Hospital of Zhejiang University between July 2007 and December 2021, with follow-up until December 2023.</div></div><div><h3>Results</h3><div>The study included 33 husband-to-wife transplant cases (Group W) and 131 wife-to-husband cases (Group H). Donors in Group W were older, had higher serum creatinine (SCr) levels, and donated heavier kidneys compared with donors in Group H (<em>p</em> < 0.05). Group W recipients had a significantly higher incidence of biopsy-proven acute rejection within two years post-transplant than Group H. The rejection reversal rate in Group W (5/6, 83.3 %) was also higher than in Group H (2/7, 28.6%) during the same period. Postoperative follow-up revealed that Group H had significantly higher SCr levels and relatively lower estimated glomerular filtration rate (eGFR) than Group W. Additionally, Group H exhibited a slightly higher mortality rate.</div></div><div><h3>Conclusions</h3><div>Wife recipients experienced a higher incidence of biopsy-proven acute rejection but demonstrated lower SCr levels and higher eGFR within two years post-transplant. This outcome may be largely explained by the greater kidney weight of male donors.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"93 ","pages":"Article 102324"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145439318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pronase treatment enhances the sensitivity of B cell flow cytometry crossmatch: A single-center data analysis Pronase治疗提高B细胞流式细胞术交叉匹配的敏感性：单中心数据分析。

IF 1.4 4区医学 Q4 IMMUNOLOGY

Transplant immunology

Pub Date : 2025-10-30 DOI: 10.1016/j.trim.2025.102325

Yan Li , Dean Sylvaria , Madeleine Billingsley , Indira Guleria

The Flow Cytometry Crossmatch (FCXM) is a vital tool in HLA laboratories for assessing transplantation immunological risk. This study evaluates FCXM results using data from 2018 to 2023, with the aim to assess the efficacy of pronase treatment in FCXM assay by comparing control serum samples in the FCXM assays performed during this time period. Tests followed our standard protocol using the BD FACSLyric™ Flow Cytometry System and BD FACSCalibur™ Flow Cytometry System, employing normal human serum (NHS) as negative control and pooled patient serum samples with strong anti-HLA antibodies as positive control. Pronase and non-pronase tests were performed and compared to rule out any false T cell positive crossmatches that could be attributable to pronase treatment.

Results showed no significant difference in delta values for T cell crossmatches between pronase-treated (MCS 256 ± 112) and non-treated (MCS 247 ± 116) groups (p = 0.253). However, B cell crossmatches had significantly higher delta values with pronase treatment (MCS 353 ± 129) versus non-treatment (MCS 300 ± 117), indicating enhanced sensitivity with pronase (p < 0.000001). Pronase-treated B cell negative controls had lower signal (MCS 245 ± 61) compared to non-treated (MCS 300 ± 73), with positive control values consistent across both groups.

Anti-CD23 analysis demonstrated a reduction in all the tests performed (MCS 372 ± 64 vs 217 ± 50), confirming efficacy of pronase treatment. These findings highlight the importance of pronase in improving FCXM sensitivity for B cells, enhancing the accuracy and reliability of FCXM protocols for better transplantation outcomes.

流式细胞仪交叉配型（FCXM）是HLA实验室评估移植免疫风险的重要工具。本研究使用2018年至2023年的数据评估FCXM结果，目的是通过比较这段时间内FCXM检测中运行的各种血清样本，评估pronase治疗在FCXM检测中的疗效。测试采用我们的标准方案，使用BD FACSCalibur™流式细胞仪系统和BD FACSCalibur™流式细胞仪系统，以正常人血清（NHS）作为阴性对照，合并具有强抗hla抗体的患者血清样本作为阳性对照。进行Pronase和非Pronase测试并进行比较，以排除可能归因于Pronase治疗的任何假T细胞阳性交叉匹配。结果显示，pronase处理组（MCS 256 ± 112）与未处理组（MCS 247 ± 116）T细胞交叉匹配δ值无显著差异（p = 0.253）。然而，pronase处理（MCS 353 ± 129）与未处理（MCS 300 ± 117）相比，B细胞交叉配型的δ值显着更高，表明pronase增强了敏感性(p

{"title":"Pronase treatment enhances the sensitivity of B cell flow cytometry crossmatch: A single-center data analysis","authors":"Yan Li , Dean Sylvaria , Madeleine Billingsley , Indira Guleria","doi":"10.1016/j.trim.2025.102325","DOIUrl":"10.1016/j.trim.2025.102325","url":null,"abstract":"<div><div>The Flow Cytometry Crossmatch (FCXM) is a vital tool in HLA laboratories for assessing transplantation immunological risk. This study evaluates FCXM results using data from 2018 to 2023, with the aim to assess the efficacy of pronase treatment in FCXM assay by comparing control serum samples in the FCXM assays performed during this time period. Tests followed our standard protocol using the BD FACSLyric™ Flow Cytometry System and BD FACSCalibur™ Flow Cytometry System, employing normal human serum (NHS) as negative control and pooled patient serum samples with strong anti-HLA antibodies as positive control. Pronase and non-pronase tests were performed and compared to rule out any false T cell positive crossmatches that could be attributable to pronase treatment.</div><div>Results showed no significant difference in delta values for T cell crossmatches between pronase-treated (MCS 256 ± 112) and non-treated (MCS 247 ± 116) groups (<em>p</em> = 0.253). However, B cell crossmatches had significantly higher delta values with pronase treatment (MCS 353 ± 129) versus non-treatment (MCS 300 ± 117), indicating enhanced sensitivity with pronase (<em>p</em> < 0.000001). Pronase-treated B cell negative controls had lower signal (MCS 245 ± 61) compared to non-treated (MCS 300 ± 73), with positive control values consistent across both groups.</div><div>Anti-CD23 analysis demonstrated a reduction in all the tests performed (MCS 372 ± 64 vs 217 ± 50), confirming efficacy of pronase treatment. These findings highlight the importance of pronase in improving FCXM sensitivity for B cells, enhancing the accuracy and reliability of FCXM protocols for better transplantation outcomes.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"93 ","pages":"Article 102325"},"PeriodicalIF":1.4,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Pre-transplant sensitization and its effect on heart transplant rejection and survival outcomes”[Transplant Immunology 92 (2025) 102264] “移植前致敏及其对心脏移植排斥反应和生存结果的影响”[移植免疫学92(2025)102264]的更正。

IF 1.4 4区医学 Q4 IMMUNOLOGY

Transplant immunology

Pub Date : 2025-10-30 DOI: 10.1016/j.trim.2025.102320

Kyung-Hwa Shin , Soo Yong Lee , Min Ho Ju , Hyun-Ji Lee

引用次数: 0

Corrigendum to “Natural killer cell KIR genotype and NKG2C phenotype in correlation to BKV infection following kidney transplantation” [Transpl Immunol. Dec 2025;93;102303] “自然杀伤细胞KIR基因型和NKG2C表型与肾移植后BKV感染相关”的勘误表。2025年12月,93;102303)。

IF 1.4 4区医学 Q4 IMMUNOLOGY

Transplant immunology

Pub Date : 2025-10-29 DOI: 10.1016/j.trim.2025.102319

Shubo Tan , Xiaobin Lin , Xueqi Li , Jianhua Long , Yuan Luo , Yao Xiao , Jianjun Li

引用次数: 0